Q&A 朝聚眼科在 2025 年一季度的经营情况如何？ 由于港股公司不披露一季报，因此朝聚眼科 2025 年一季度的整体情况与去年 同期（2024 年）基本持平。收入端和利润端的数据尚未合并，但 1-2 月份屈 光手术需求增长带动了消费眼科的增长。然而，3 月份这一增长有所回落。因 此，整体来看，一季度与去年同期相比持平。此外，2024 年一季度基础眼科 和消费眼科未受到晶体集采和消费降级影响，基数较高。 朝聚眼科 20250523 摘要 朝聚眼科 2024 年收入同比增长 2.6%，但经调整净利润同比下降 9.1%，主要受消费降级和新医院爬坡期影响。基础眼科受益于并购医院 实现增长，但消费眼科受屈光手术降价影响，毛利率下降 6.5%。 白内障手术量增加，飞秒激光白内障手术增长显著（43%），抵消了集 采带来的单价下降影响，但国产晶体降价对收入造成压力。高端晶体使 用率提升，一季度高端晶体收入占比达 60%。 全飞秒激光技术在多家医院推广，但受消费降级影响，价格下调约 2000 元，对收入产生影响。虽年初因征兵需求有所增长，但三月需求 回落，未来需关注暑期消费情况。 集采政策和 DIP 政策对不同区域产生不同 ...

Financial Performance - For the year ended December 31, 2024, the company reported revenue of RMB 1,405,454,000, representing an increase from RMB 1,369,505,000 in 2023, which is a growth of approximately 2.0%[5] - The gross profit for 2024 was RMB 611,302,000, with a gross margin of 43.5%, down from 45.4% in 2023[5] - The net profit for 2024 was RMB 186,210,000, resulting in a net profit margin of 13.2%, compared to 16.1% in the previous year[5] - The company reported a total equity of RMB 2,326,151,000 as of December 31, 2024, down from RMB 2,378,425,000 in 2023[5] - Total revenue reached RMB 1.405 billion, maintaining a healthy gross margin despite challenges from artificial lens procurement and DIP/DRG policies[15] - Net profit achieved RMB 186 million, with net cash flow from operating activities amounting to RMB 354 million, indicating strong financial health[15] - Total gross profit for the group was RMB 611.3 million for the year ended December 31, 2024, a decrease of 1.6% from RMB 621.1 million in 2023[37] - The company's adjusted net profit for the year ended December 31, 2024, is RMB 202.7 million, a decrease of 9.2% from RMB 223.1 million in 2023, with an adjusted net profit margin of 14.4% compared to 16.3% in the previous year[57] Operational Efficiency and Strategy - The company implemented a "Excellence Plan" to optimize management and resource allocation, enhancing operational efficiency across hospitals[12] - The company believes its cluster operation model enhances market penetration, operational efficiency, and profitability[9] - The company plans to enhance operational efficiency and service quality through systematic, standardized, professional, refined, and intelligent management strategies in 2025[16] - Marketing strategies were refined using data-driven approaches to improve marketing efficiency and ensure effective outreach to target patient groups[13] - Continuous investment in advanced medical equipment and precise pricing strategies for high-end ophthalmic services contributed to improved patient experiences[15] Market Expansion and Services - The company is focusing on expanding its consumer eye care services while maintaining its foundational eye care services, responding to the increasing consumer demand in China[7] - The group operates a network of 31 ophthalmology hospitals across 7 provinces, municipalities, and autonomous regions in China as of December 31, 2024[20] - The group aims to enhance market share in existing regions through strategic initiatives like the "Excellence Program" and "Wutong Program" while focusing on patient outcomes[19] - The group plans to continue investing in advanced medical equipment and treatment solutions to improve service quality and patient retention rates[25] - The consumption ophthalmology services accounted for 50.3% of total revenue in 2024, making it the primary revenue source for the group[24] - Basic ophthalmology services contributed approximately 49.6% to total revenue in 2024, marking it as another major revenue source[25] Human Resources and Talent Management - As of December 31, 2024, the group employed 1,464 full-time medical professionals, including 296 physicians, 625 nurses, and 543 other professionals[38] - The company has implemented systematic training and education programs for employees, ensuring a well-proportioned mix of medical professionals and enhancing clinical skills through both internal and external training[86] - The company is committed to maintaining gender diversity within its workforce and enhancing employee value as a key asset[124] Acquisitions and Investments - The group has made significant acquisitions in the healthcare sector, enhancing its service offerings and market presence[32] - The group has acquired multiple hospitals, including Bayannur Hospital and Beijing Clinic in September 2023, and Yinchuan Hospital in March 2023[32] - The group plans to continue expanding its network in the North China region and aims to acquire more hospitals in the near future[40] Financial Position and Cash Flow - The net cash inflow from operating activities for the year ended December 31, 2024, was RMB 354.4 million, down from RMB 372.6 million in 2023[61] - The company reported a net increase in cash and cash equivalents of RMB 317.3 million for the year ended December 31, 2024, compared to a decrease of RMB 481.3 million in 2023[61] - The total capital commitments as of December 31, 2024, amounted to approximately RMB 564 million, a decrease from RMB 715 million in 2023[66] Risk Management and Compliance - The company faces risks related to price controls and coverage limits under public health insurance plans, which may impact pricing of services and products[112] - The company has a credit risk management policy in place to monitor and manage potential losses from counterparties failing to meet obligations[77] - The company has maintained compliance with relevant laws and regulations, with no significant violations reported as of December 31, 2024[118] Shareholder and Governance - The company adopted a share incentive plan on May 10, 2022, granting a total of 16,330,994 shares to 311 employees and directors as of December 31, 2024, with a total allowable grant of 54,803,769 shares under the plan[85] - The company has established an audit committee consisting of three independent non-executive directors to oversee financial reporting and risk management[14] - All independent non-executive directors confirmed their independence for the period from January 1, 2024, to December 31, 2024[167] Environmental and Social Responsibility - The company has a commitment to environmental protection and has established policies for the proper handling and disposal of medical waste, ensuring compliance with applicable laws and regulations[115] - The company is committed to fulfilling social responsibilities and promoting employee welfare, aiming for sustainable growth[116]

尽管毛利率受行业政策调整影响，但通过成本管控与流程优化，全年毛利率维持在43.5%。此外，公 司"基础+消费"双轮模式初见成效，高端服务收入占比持续提升，差异化竞争力逐步增强。 从当前市场环境来看，眼科医疗行业的高需求刚性为朝聚眼科的长期发展提供了支撑。一方面，人口老 龄化加速、青少年近视防控需求攀升，推动基础眼科服务需求持续增长；另一方面，消费升级趋势下， 屈光手术等高端服务市场潜力逐步释放。尽管短期内行业面临医保政策调整与竞争加剧的压力，但公司 通过"卓越计划"优化采购流程、提升服务效率，展现出对政策环境的适应能力。 3月27日，朝聚眼科（02219.HK）发布2024年全年业绩报告。数据显示，公司全年实现收入14.05亿元人 民币，同比增长2.6%；经调整净利润2.03亿元，净利润率14.4%；经营活动现金流净额达3.54亿元，展 现出较强的资金周转能力。尽管行业竞争加剧，公司通过业务优化、区域深耕及社会责任践行，维持了 经营韧性。 报告显示，基础眼科收入同比增加6.7%至6.98亿元。得益于优化诊疗服务流程，朝聚眼科通过个性化服 务提高单客户贡献值以抵消下半年晶体集采的影响；消费眼科收入受整体经济下行 ...

Financial Performance - The group's revenue increased by 2.6% from RMB 1,369.5 million for the year ended December 31, 2023, to RMB 1,405.5 million for the year ended December 31, 2024[2]. - The group's profit before tax decreased by 12.2% from RMB 299.2 million to RMB 262.7 million, with a profit before tax margin dropping from 21.9% to 18.7%[2]. - The group's net profit fell by 15.6% from RMB 220.7 million to RMB 186.2 million, resulting in a net profit margin decline from 16.1% to 13.2%[3]. - The adjusted net profit under non-IFRS decreased by 9.1% from RMB 223.1 million to RMB 202.7 million, with the adjusted net profit margin dropping from 16.3% to 14.4%[3]. - The group's gross profit margin decreased from 45.4% to 43.5%[7]. - The group's EBITDA under non-IFRS was RMB 374.1 million, slightly down from RMB 377.3 million in the previous year[7]. - The total gross profit for the group was RMB 611.3 million, a decrease of 1.6% from RMB 621.1 million in the previous year[18]. - The company's net asset value was RMB 2,326,151 thousand, down from RMB 2,378,425 thousand in 2023, reflecting a decrease of 2.2%[96]. - The company reported a significant increase in cash and cash equivalents, reaching RMB 780,785 thousand, compared to RMB 463,437 thousand in 2023, an increase of 68.4%[95]. Revenue Sources - The consumption ophthalmology services accounted for 50.3% of total revenue in 2024, making it the primary revenue source for the group[14]. - Basic ophthalmology services contributed approximately 49.6% to total revenue in 2024, serving as another major revenue source[17]. - Revenue from consumer ophthalmology services decreased by 0.4% from RMB 709.2 million to RMB 706.4 million, indicating a slowdown in the Chinese consumer market[30]. - Revenue from basic ophthalmology services increased by 6.7% from RMB 654.0 million to RMB 697.8 million, driven by enhanced marketing activities and improved patient conversion rates[31]. Operational Metrics - Outpatient visits increased to 1,137,742 in 2024 from 1,128,719 in 2023, with an average spending per visit rising from RMB 698 to RMB 713[9]. - Inpatient visits rose to 72,120 in 2024 from 67,258 in 2023, while average spending per inpatient visit decreased from RMB 7,109 to RMB 6,914[9]. - The optical center recorded 105,354 customer visits in 2024, down from 120,184 in 2023, with average sales price increasing from RMB 806 to RMB 900[9]. Dividends and Shareholder Returns - The board proposed a final dividend of HKD 0.1193 per share for the year ended December 31, 2024, down from HKD 0.2208 per share in 2023[4]. - The total interim dividend declared and paid for the six months ended June 30, 2024, was approximately HKD 90.28 million (equivalent to RMB 82.5 million)[4]. - The company has declared a final dividend of HKD 0.2208 per share and a special dividend of HKD 0.0767 per share, totaling approximately HKD 205.5 million (approximately RMB 187.1 million) for the year ended December 31, 2023[88]. Employee and Operational Structure - As of December 31, 2024, the group employed a total of 1,464 full-time medical professionals, including 296 doctors, 625 nurses, and 543 other professionals[20]. - The company has 267 registered full-time ophthalmologists as of December 31, 2024, contributing to its medical expertise[79]. - The total employee benefit expenses increased to RMB 421,240 in 2024 from RMB 377,754 in 2023, reflecting a growth of 11.5%[115]. - Employee compensation includes basic salary, performance-related bonuses, and discretionary year-end bonuses, with regular performance evaluations for salary reviews[80]. Strategic Initiatives and Future Plans - The group plans to continue expanding its network in the North China region and aims to acquire more hospitals in the near future[26]. - The company plans to invest HKD 200 million in research and development for innovative eye care solutions over the next two years[132]. - The company aims to improve operational efficiency, targeting a 5% reduction in costs by optimizing supply chain management[132]. - Future guidance indicates a potential revenue growth of 10-15% annually over the next three years[132]. Financial Position and Liabilities - The total liabilities decreased to RMB 554,765 thousand from RMB 544,381 thousand in 2023, indicating a slight increase in financial obligations[96]. - The total interest-bearing borrowings as of December 31, 2024, amounted to RMB 40,629,000, compared to RMB 7,153,000 in 2023, showing a significant increase[126]. - Trade receivables increased by 33.6% from RMB 55.7 million for the year ended December 31, 2023, to RMB 74.4 million for the year ending December 31, 2024, due to growth in basic ophthalmic services[45]. Compliance and Governance - The company has confirmed compliance with corporate governance codes and standards since January 1, 2024[67]. - The audit committee and independent auditors confirmed that the annual performance for the year ending December 31, 2024, complies with applicable accounting standards and regulations[84]. - The company has established an audit committee consisting of three independent non-executive directors to oversee financial reporting and risk management[70].

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 734,287,000, representing a 6.0% increase from RMB 692,688,000 in the same period of 2023[18]. - Gross profit for the same period was RMB 335,974,000, up 4.0% from RMB 322,922,000 year-on-year[18]. - Net profit decreased by 9.0% to RMB 133,620,000 from RMB 146,912,000 in the previous year[18]. - The adjusted net profit under non-IFRS was RMB 144,753,000, a 6.0% increase from RMB 136,539,000 in the prior year[18]. - Total comprehensive income for the period was RMB 137,972,000, down from RMB 164,608,000 in the previous year[103]. - The company's total equity as of June 30, 2024, was RMB 2,341,006,000, a decrease from RMB 2,378,425,000 at the end of 2023[105]. - The basic earnings per share for the period was RMB 0.20, unchanged from the previous year[102]. - The company reported a net profit of RMB 136,453,000 for the six months ended June 30, 2024, compared to RMB 150,613,000 for the same period in 2023, representing a decrease of approximately 9.4%[107]. Assets and Liabilities - Total assets as of June 30, 2024, were RMB 2,835,653,000, down 3.0% from RMB 2,922,806,000 at the end of 2023[19]. - Total liabilities were RMB 494,647,000, a decrease of 9.1% from RMB 544,381,000[19]. - Cash and cash equivalents decreased by 14.6% to RMB 395,734,000 from RMB 463,437,000[19]. - Trade receivables increased by 21.2% from RMB 55.7 million to RMB 67.5 million, primarily due to growth in basic ophthalmic services leading to higher medical insurance receivables[50]. - Trade payables increased by 13.0% from RMB 55.4 million as of December 31, 2023, to RMB 62.6 million as of June 30, 2024, driven by business expansion[54]. Revenue Breakdown - Revenue from consumer ophthalmology services rose by 4.3% from RMB 361.1 million to RMB 376.5 million, driven by market expansion through new hospital and optical center establishments and acquisitions[37]. - Revenue from basic ophthalmology services increased by 7.7% from RMB 331.6 million to RMB 357.2 million, attributed to enhanced marketing activities and improved patient service processes[38]. - Consumer ophthalmic services accounted for 51.3% of total revenue, a decrease of approximately 0.8 percentage points from the previous year[28]. - Basic ophthalmic services represented 48.6% of total revenue, an increase of about 0.7 percentage points compared to the previous year[29]. Operational Highlights - Outpatient visits increased to 571,087 in the six months ended June 30, 2024, from 531,714 in the same period of 2023, representing a growth of approximately 7.4%[24]. - The average spending per outpatient visit rose to RMB 764, up from RMB 752, indicating an increase of about 1.6%[24]. - The number of inpatient visits increased to 35,814, compared to 32,922 in the previous year, reflecting a growth of approximately 8.6%[24]. - The company expanded its network to 31 ophthalmology hospitals and 29 optical centers across seven provinces and municipalities in China as of June 30, 2024[23]. Strategic Initiatives - The company aims to focus more on consumer eye care services while maintaining its advantages in basic eye care services[21]. - The company believes its advanced technology and equipment will enhance brand recognition and customer loyalty, contributing to competitive advantages in myopia prevention[21]. - The company aims to strengthen its leading position in North China and enhance its market presence in key areas like the Yangtze River Delta through new hospital constructions and acquisitions[34]. - The group plans to implement a centralized management model focused on regional center hospitals to improve resource efficiency[35]. Cost and Expenses - The group's sales cost increased by 7.7% from RMB 369.8 million for the six months ended June 30, 2023, to RMB 398.3 million for the six months ending June 30, 2024, primarily due to fixed costs and expenses related to new hospital openings and upgrades[39]. - Sales and distribution expenses increased by 22.8% from RMB 51.3 million to RMB 63.0 million, driven by marketing and advertising costs associated with new acquisitions and existing hospitals[42]. - Administrative expenses decreased by 3.8% from RMB 110.6 million to RMB 106.4 million, primarily due to cost control measures[43]. Cash Flow and Investments - The net cash flow from operating activities for the six months ended June 30, 2024, was RMB 174.5 million, a decrease from RMB 194.8 million in the same period of 2023[53]. - The net cash outflow from investing activities was RMB 18.8 million, significantly improved from RMB 589.4 million in the previous year[53]. - The net cash outflow from financing activities was RMB 224.3 million, compared to RMB 153.8 million in the prior year, primarily due to dividend payments[53]. Shareholder Information - The company declared an interim dividend of HKD 0.1307 per share for the six months ending June 30, 2024, compared to no dividend for the same period in 2023[63]. - The company has 2,648 full-time employees as of June 30, 2024, including 1,458 hospital professionals and 101 optical center professionals[71]. - The company has established an audit committee to oversee financial reporting and risk management systems[66]. Future Outlook - The company plans to acquire hospitals in new markets with high demand for ophthalmic services, allocating 44.80% of the net proceeds for this purpose[68]. - Future guidance indicates a projected revenue growth of 20% for the full year 2024[162]. - The company aims to enhance its outpatient services, expecting a 25% increase in patient visits by mid-2025[162].

Revenue Growth - The group's revenue increased by 6.0% from RMB 692.7 million in the same period of 2023 to RMB 734.3 million for the six months ended June 30, 2024[2]. - The group's revenue increased by 6.0% from RMB 692.7 million for the six months ended June 30, 2023, to RMB 734.3 million for the six months ended June 30, 2024, primarily due to acquisitions of ophthalmology hospitals and optical centers[8]. - Revenue from consumer ophthalmology services rose by 4.3% from RMB 361.1 million to RMB 376.5 million, driven by market expansion and the introduction of new hospitals and optical centers[21]. - Revenue from basic ophthalmology services increased by 7.7% from RMB 331.6 million to RMB 357.2 million, supported by enhanced marketing activities and improved patient service processes[22]. - Revenue for the six months ended June 30, 2024, was RMB 734,287 thousand, an increase of 6.0% compared to RMB 692,688 thousand for the same period in 2023[67]. - Revenue from outpatient services was RMB 436,163,000 for the six months ended June 30, 2024, compared to RMB 399,816,000 in 2023, reflecting an increase of 9.1%[87]. Profitability - Gross profit rose by 4.1% from RMB 322.9 million to RMB 336.0 million, with a gross margin decrease from 46.6% to 45.8%[2]. - Profit before tax decreased from RMB 184.6 million to RMB 179.6 million, resulting in a profit margin decline from 26.6% to 24.5%[2]. - Net profit fell by 9.1% from RMB 146.9 million to RMB 133.6 million, with a net profit margin decreasing from 21.2% to 18.2%[2]. - Basic earnings per share decreased from RMB 0.21 to RMB 0.20[3]. - Non-IFRS adjusted net profit increased by 6.1% from RMB 136.5 million to RMB 144.8 million, with an adjusted net profit margin of 19.7%[4]. - The total profit attributable to equity holders of the parent company for the six months ended June 30, 2024, was RMB 136,453,000, a decrease of 9.4% from RMB 150,613,000 for the same period in 2023[94]. Operational Metrics - The number of ophthalmology hospitals operated by the group increased from 26 to 31[3]. - Outpatient visits increased to 571,087 in the six months ended June 30, 2024, compared to 531,714 in the same period of 2023, representing a growth of approximately 7.4%[7]. - Inpatient visits increased to 35,814 in the six months ended June 30, 2024, compared to 32,922 in the same period of 2023, marking a growth of approximately 8.7%[7]. - The optical center customer visits totaled 51,774 in the six months ended June 30, 2024, down from 58,317 in the same period of 2023, a decline of approximately 11.8%[7]. - The group operates a network of 31 ophthalmology hospitals and 29 optical centers across seven provinces and municipalities in China as of June 30, 2024[6]. Cost and Expenses - The group's cost of sales grew by 7.7% from RMB 369.8 million to RMB 398.3 million, primarily due to fixed costs and expenses related to new hospital openings and renovations[23]. - Sales and distribution expenses increased by 22.8% from RMB 51.3 million for the six months ended June 30, 2023, to RMB 63.0 million for the six months ended June 30, 2024, primarily due to increased marketing and advertising costs associated with new hospital acquisitions and existing hospital activities[26]. - Administrative expenses decreased by 3.8% from RMB 110.6 million for the six months ended June 30, 2023, to RMB 106.4 million for the six months ended June 30, 2024, mainly due to cost control measures[27]. - The gross profit from consumer ophthalmic services was RMB 183.0 million, a decrease of 1.6% compared to RMB 185.9 million for the same period in 2023, primarily due to a 10.4% increase in costs[14]. - The gross profit from basic ophthalmic services for the same period was RMB 152.9 million, an increase of 11.6% compared to RMB 137.0 million in 2023, driven by a 7.7% increase in revenue and cost allocation[14]. Cash Flow and Liquidity - For the six months ended June 30, 2024, the net cash flow from operating activities was RMB 174.5 million, a decrease from RMB 194.8 million in the same period of 2023[38]. - The net cash flow used in investing activities was RMB (18.8) million, significantly improved from RMB (589.4) million year-on-year[38]. - The net cash flow used in financing activities was RMB (224.3) million, compared to RMB (153.8) million in the previous year, primarily due to dividend payments[38]. - The company’s main sources of liquidity include cash generated from operations and financing through debt and equity[37]. - The company reported a net cash outflow from financing activities of RMB 224,348,000, compared to RMB 153,764,000 in the previous year, indicating increased financing costs[74]. Market and Strategic Outlook - The Chinese ophthalmic medical services market is expected to reach RMB 223.1 billion by 2024, with the North China market projected to grow to RMB 33.7 billion[18]. - The company aims to enhance management capabilities through systematic, standardized, professional, refined, and intelligent development over the next decade[18]. - The group plans to continue expanding its network in North China and strengthen its market position in key regions like the Yangtze River Delta[19]. - The company aims to acquire hospitals in new markets with high demand for ophthalmic services, allocating HKD 716.35 million, which is 44.80% of the total proceeds[58]. - The company is investing RMB 50 million in R&D for new ophthalmic technologies, aiming to launch two innovative products by Q4 2024[102]. Employee and Talent Management - The group employed a total of 1,458 medical professionals as of June 30, 2024, up from 1,316 in 2023, including 302 doctors, 622 nurses, and 534 other professionals[15]. - The company emphasizes talent acquisition and retention, focusing on the development of young professionals to strengthen its talent pool[18]. - The company has granted a total of 13,396,724 shares under its share incentive plan to 224 employees, with 57,613,831 shares available for future grants as of June 30, 2024[62]. - The company has not experienced any significant labor disputes or strikes that would impact operations as of June 30, 2024[64]. Dividends and Shareholder Returns - The board declared an interim dividend of HKD 0.1307 per share[3]. - The interim dividend declared for each ordinary share was 13.07 HK cents, totaling approximately HKD 92,444,000, compared to no interim dividend for the same period in 2023[92]. - The company declared a final dividend of HKD 142,256,000 for the year ended December 31, 2023, compared to HKD 111,523,000 for the previous year[91]. Compliance and Governance - The independent auditor has reviewed the interim financial results, confirming compliance with applicable accounting standards and regulations[65]. - The company has established an audit committee consisting of three independent non-executive directors to oversee financial reporting and internal controls[56]. - The company has adopted a standard code for securities trading by directors, confirming compliance since January 1, 2024[55].

我们眼科整体行业都恢复到一个相对平稳的增长速度所以第一季度我们潮区眼科收入的增长大概都在高单位数增长速度所以我们相对其他同业的话我们估计也是在一个行业的平均或是以上的水平的来增长了 我们估计今年高峰期可能会在暑假的时期 大约是六到八月的时候因为在小孩眼科的时光方面相对应该会比较好 今年我们的业务方面主要都会比较集中在适光方面然后区光跟白雷站整体我们觉得今年 收入的话可能增长是高单位数刚刚说过了利润也可能跟去年同期差不多因为今年第一季度整体的话相比我们去年同期是去年是一个比较高比较高高一点的一个high base就是那个 去年同期相对比较高的基数所以今年虽然我们增长相对过往是不错但是还是 只有高单位数的增长其他估计也跟同业也差不多可能看看其他投资人有没有什么问题我们直接回答另外可能国产方面对我们公司来说现在暂时没有很明显的一个影响因为国产的话在内容还没体现出来可能要带到去 下半年可能八九月份可能会对整体的收入都有点影响估计 好的,谢谢韦剑总,然后这个如果有问题的投资人可以直接去做这个提问,然后我这边看到会带回提问哈,然后我这边其实也有些问题跟这个要请教,首先就是A制度的话,刚才其实韦剑总有提到我们是一个高单位数 ...

我们眼科整体那个行业都回复到一个相对平稳的一个增长速度所以第一季度我们潮区眼科收入的增长大约都在高单位数这个增长速度 所以我们相对其他同业的话我们估计也是在一个行业的平均或是以上的水平的来增长了我们估计今年可能高峰期可能会在暑假的时期 大约是六到八月的时候因为在小孩眼科的视光方面相对业务会比较好今年我们的业务方面主要都会比较集中在视光方面然后曲光跟白内障 整体我们觉得今年收入的话可能增长是高单位数刚刚说过了利润也可能跟去年同期差不多 因为今年第一季度整体的话相比我们去年同期是去年是一个比较高比较高高一点的一个i base就是去年同期相对比较高的基数 所以今年虽然我们增长相对过往是不错但是还是只有高单位数的增长其他估计也跟同业也差不多可能看看其他投资人有没有什么问题我们直接回答 另外可能国产方面对我们公司来说现在暂时没有很明显的一个影响 因为国产的话在内部还没体现出来可能要待到去下半年可能八九月份吧可能那个可能会对整体的收入都有点影响估计 好的好的谢谢韦剑总啊然后这个如果有问题投资人可以直接去做这个提问然后我这边看到会带回提问哈然后我这边其实也有些问题跟这个要请教首先就是AZ2的话刚才其实韦剑总有提到我们是一个 ...

Chaoju Eye Care Holdings Limited 朝聚眼科醫療控股有限公司 (於開曼群島註冊成立的有限公司) 股份代號：2219 2023 年報 目錄 公司資料2 財務摘要4 公司概況5 主席報告6 管理層討論及分析9 董事及高級管理層 29 董事會報告 36 企業管治報告 67 獨立核數師報告 81 綜合損益表 86 綜合其他全面收益表 87 綜合財務狀況表 88 綜合權益變動表 90 綜合現金流量表 92 財務報表附註 94 詞彙及定義 184 公司資料 | --- | --- | |-------------------------------------------|------------------------------------| | | | | 董事會 | 薪酬委員會 | | 執行董事 | 寶山先生 （主席） | | 張波洲先生 （董事長兼首席執行官） | 李建濱先生 | | 張小利女士 | 張波洲先生 | | 張俊峰先生 | | | 張光弟先生 | 提名委員會 | | 非執行董事 | 張波洲先生 （主席） 寶山先生 | | Richard Chen Mao 先生 | 何明 ...

[Ta朝ble_聚Sto眼ckN科am（eRp2tT2yp1e9] ） 公司研究/公司点评 营收稳健增长，期待 24 年更进一步 [投Ta资bl评e_级Ra：nk买] 入（维持） 主要观点： 报告日期： 2024-04-10 [T事ab件le_：Summary] 2024年3月26日公司发布公告，2023年实现营业收入1369.5百万 [收Ta盘bl价e_（Ba港se元Da）ta] 3.85 元，同比+38.3%，实现税前净利润299.2百万元，同比+25.1%，实 近12个月最高/最低（港元） 6.30/3.50 现经调净利润223.1百万元，同比+19.8%；每股盈利0.33元。 总股本（亿股） 7.08 流通H股（亿股） 7.08  点评：  基础眼科业务增长强劲，需求快速恢复 流通股比例（%） 100.00 公司2023年营收水平稳步增长、利润同比增长，疫后公司体内 总市值（亿元港币） 27 医院快速恢复运转。拆分收入结构，2023年公司消费眼科服务 公司价格与恒生指数走势比较 收入 7.09 亿元（+30.64%），基础眼科服务收入 6.54 亿元 （+39.54%）；公司整体毛利率45.40 ...